nach oben

Die Urologie

Erschienen in:

05.08.2016 | Harnblasenkarzinom | Leitthema

Kurzform der S3-Leitlinie Harnblasenkarzinom

verfasst von: Prof. Dr. M. Retz, J. E. Gschwend, P. Maisch

Erschienen in: Die Urologie | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Harnblasenkarzinom ist die zweithäufigste urologische Tumorerkrankung. Die S3-Leitlinie Harnblasenkarzinom wurde gemeinsam mit dem Leitlinienprogramm Onkologie der Arbeitsgemeinschaft Medizinisch Wissenschaftlicher Fachgesellschaften e. V. (AWMF), der Deutschen Krebsgesellschaft und der Deutschen Krebshilfe unter Beteiligung von weiteren 31 medizinischen Fachgesellschaften erstellt. Die Kurzversion soll Auszüge an Empfehlungen aus der S3-Leitlinie Blasenkarzinom vorstellen. Die Empfehlungen basieren auf systematischen Literaturrecherchen und Expertenmeinungen und wurden von Blasenkarzinomexperten und Gesellschaften abgestimmt. Die Langversion der S3-Leitlinie Harnblasenkarzinom kann unter dem Link http://leitlinienprogramm-onkologie.de/ eingesehen werden.

Goessl C et al (1997) Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol 157(2):480–481PubMedCrossRef

Herranz-Amo F et al (1999) Need for intravenous urography in patients with primary transitional carcinoma of the bladder? Eur Urol 36(3):221–224PubMedCrossRef

Palou J et al (2005) Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 174(3):859–861 (discussion 861)PubMedCrossRef

Millan-Rodriguez F et al (2000) Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol 164(4):1183–1187PubMedCrossRef

Van Der Molen AJ et al (2008) CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol 18(1):4–17PubMedCrossRef

Hermann GG et al (2011) Fluorescence – guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in T a/T1 patients: a randomized two – centre study. BJU Int 108(8 b):E297–E303PubMedCrossRef

Stenzl A et al (2010) Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 184(5):1907–1913PubMedPubMedCentralCrossRef

Geavlete B et al (2010) HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer – re-TURBT recurrence rates in a prospective, randomized study. Urology 76(3):664–669PubMedCrossRef

Karaolides T et al (2012) Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology 80(2):354–359PubMedCrossRef

10.

Yuan H et al (2013) Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS ONE 8(9):e74142PubMedPubMedCentralCrossRef

11.

Shen P et al (2012) Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis. BJU Int 110(6 Pt B):E209–E215PubMedCrossRef

12.

Yang LP (2014) Hexaminolevulinate blue light cystoscopy: A review of its use in the diagnosis of bladder cancer. Mol Diagnosis Ther 18(1):105–116CrossRef

13.

Rink M et al (2013) Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol 64(4):624–638PubMedCrossRef

14.

Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63(4):682–686 (discussion 686–7)PubMedCrossRef

15.

Sylvester RJ, van der Adrian MA, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964–1970PubMedCrossRef

16.

Sylvester RJ et al (2010) Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 57(5):766–773PubMedCrossRef

17.

Malmstrom PU et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247–256PubMedCrossRef

18.

Shang PF et al (2011) Intravesical bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 5:Cd006885PubMed

19.

Fernandez-Gomez J et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol 60(3):423–430PubMedCrossRef

20.

Shelley MD et al (2001) A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88(3):209–216PubMedCrossRef

21.

Shelley MD et al (2004) Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93(4):485–490PubMedCrossRef

22.

Gardmark T et al (2007) Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int 99(4):817–820PubMedCrossRef

23.

Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169(1):90–95PubMedCrossRef

24.

Lamm DL et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124–1129PubMedCrossRef

25.

Tilki D et al (2010) Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol 58(1):112–117PubMedCrossRef

26.

Gray PJ et al (2014) Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys 88(5):1048–1056PubMedCrossRef

27.

Herr HW et al (2004) Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 22(14):2781–2789PubMedCrossRef

28.

May M et al (2011) Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol 18(7):2018–2025PubMedCrossRef

29.

Simone G et al (2013) Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy. Int J Urol 20(4):390–397PubMedCrossRef

30.

Herr HW et al (2002) Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 167(3):1295–1298PubMedCrossRef

31.

Weisbach L et al (2013) Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. Int Urol Nephrol 45(6):1561–1567PubMedCrossRef

32.

Kitamura H, Masumori N, Tsukamoto T (2011) Role of lymph node dissection in management of bladder cancer. Int J Clin Oncol 16(3):179–185PubMedCrossRef

33.

Karl A et al (2009) The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 55(4):826–835PubMedCrossRef

34.

Zehnder P et al (2011) Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 186(4):1261–1268PubMedCrossRef

35.

Koppie TM et al (2006) Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer 107(10):2368–2374PubMedCrossRef

36.

Colombo JR Jr., Haber GP, Gill IS (2008) Laparoscopic partial nephrectomy in patients with compromised renal function. Urology 71(6):1043–1048CrossRef

37.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF) S3 Leitlinie Kolorektales Karzinom. Langversion 1.0. http://leitlinienprogramm-onkologie.de/Leitnienien,7.0.html. Zugegriffen: 18.07.2016

38.

Millan M et al (2010) Preoperative stoma siting and education by stomatherapists of colorectal cancer patients: a descriptive study in twelve Spanish colorectal surgical units. Colorectal Dis 12(7 Online):e88–92PubMed

39.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF) (2013) S3 Leitlinie Kolorektales Karzinom. Langversion 1.0. http://leitlinienprogramm-onkologie.de/Kolorektales-Karzinom.62.0.html. Zugegriffen: 18.07.2016

40.

Bass EM et al (1997) Does preoperative stoma marking and education by the enterostomal therapist affect outcome? Dis Colon Rectum 40(4):440–442PubMedCrossRef

41.

Colwell JC, Gray M (2007) Does preoperative teaching and stoma site marking affect surgical outcomes in patients undergoing ostomy surgery? J Wound Ostomy Continence Nurs 34(5):492–496PubMedCrossRef

42.

Chaudhri S et al (2005) Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial. Dis Colon Rectum 48(3):504–509PubMedCrossRef

43.

Schwenk W (2015) Moderne perioperative Behandlung. In: Kreis ME (Hrsg) Moderne Chirurgie des Rektumkarzinoms. Springer, Berlin

44.

Glatzle J, Longin I, Gruber G (2015) Stomaanlage und Stomatherapie. In: Kreis ME (Hrsg) Moderne Chirurgie des Rektumkarzinoms. Springer, Berlin

45.

Sternberg CN et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64(12):2448–2458PubMedCrossRef

46.

Mead GM et al (1998) A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 78(8):1067–1075PubMedPubMedCentralCrossRef

47.

von der Maase H et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077PubMed

48.

Bellmunt J et al (2012) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30(10):1107–1113PubMedPubMedCentralCrossRef

49.

Sternberg CN et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19(10):2638–2646PubMed

50.

Bellmunt J et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27(27):4454–4461PubMedCrossRef

51.

Bellmunt J et al (2013) Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 24(6):1466–1472PubMedCrossRef

52.

Sylvester RJ et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–465 (discussion 475–7)PubMedCrossRef

53.

NICE (2015) Bladder cancer: diagnosis and management. https://www.nice.org.uk/guidance/ng2. Zugegriffen 18.07.2016

Titel: Kurzform der S3-Leitlinie Harnblasenkarzinom
verfasst von: Prof. Dr. M. Retz
J. E. Gschwend
P. Maisch
Publikationsdatum: 05.08.2016
Verlag: Springer Berlin Heidelberg
Schlagwörter: Harnblasenkarzinom
Harnblasenkarzinom
Urothelkarzinom
Zystektomie
Urografie
Urothelkarzinom
Erschienen in: Die Urologie / Ausgabe 9/2016
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-016-0195-1

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Kurzform der S3-Leitlinie Harnblasenkarzinom

Zusammenfassung

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

Nichtmuskelinvasives Harnblasenkarzinom

S3-Leitlinie Harnblasenkarzinom

Einsatz von GnRH-Antagonisten vs. -Agonisten

BDU-Journal - Berufspolitik

Qualität in der Urologie

Nationale Zweitmeinungsnetzwerke Hodentumoren und Peniskarzinom

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie